ameri100 embodies a value system of ambition, mastery, excitement, reliability and integrity. with these values, the company is becoming an emerging global leader in sap technologies. ameri100, founded in 2013 has rapidly grown through strategic acquisitions. headquartered in princeton, new jersey, with offices in new york, georgia, kansas, pennsylvania, arizona, toronto- canada and bangalore, mumbai, chennai in india, ameri100 brings 500+ of its own best-in-class resources. the company has also evolved a unique partner ecosystem, which adds more than 4500+ resources to its delivery muscle power. ameri100 deals with sap enterprise services, digital transformation, cloud solutions, business intelligence & analytics, mobile applications and professional services. the company is also making strategic investments in artificial intelligence (ai), internet of things (iot) and robotic process automation (rpa). insight to impact!
Company profile
Ticker
ENVB
Exchange
Website
CEO
Brent Kelton
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMERI Holdings, Inc., SPATIALIZER AUDIO LABORATORIES INC
SEC CIK
Corporate docs
Subsidiaries
Jay Pharma Inc. • 1306432 B.C. Unlimited Liability Company • Enveric Biosciences Canada, Inc. • MagicMed USA, Inc. • Akos Biosciences, Inc. • Enveric Therapeutics Pty. Ltd. • Delaware, USA • Adelaide, Australia ...
IRS number
954484725
ENVB stock data
Latest filings (excl ownership)
8-K
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
26 Mar 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive
19 Mar 24
424B5
Prospectus supplement for primary offering
11 Mar 24
8-K
Entry into a Material Definitive Agreement
11 Mar 24
8-K
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds
29 Feb 24
8-K
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
21 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Feb 24
424B3
Prospectus supplement
24 Jan 24
EFFECT
Notice of effectiveness
23 Jan 24
Latest ownership filings
4
Joseph Edward Tucker
26 Feb 24
4
Peter J. Facchini
26 Feb 24
4
Kevin Michael Coveney
26 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
SC 13G/A
Hudson Bay Capital Management LP
5 Feb 24
4
FRANK PASQUALONE
19 Sep 23
4
Kevin Michael Coveney
14 Mar 23
3
Kevin Michael Coveney
14 Mar 23
SC 13G
AdvisorShares Trust
14 Feb 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 20 |
Opened positions | 4 |
Closed positions | 4 |
Increased positions | 2 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 587.68 mm |
Total shares | 5.82 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
TOP Invest | 2.30 mm | $13.61 mm |
Stefansky David | 1.15 mm | $6.80 mm |
TAF | 934.26 k | $3.98 mm |
Chex Associates | 882.79 k | $5.23 mm |
Intracoastal Capital | 206.14 k | $0.00 |
AdvisorShares Trust | 116.30 k | $0.00 |
AdvisorShares Investments | 100.43 k | $338.45 mm |
Alpha Capital Anstalt | 47.03 k | $0.00 |
BLK Blackrock | 29.58 k | $99.68 mm |
Renaissance Technologies | 17.17 k | $58.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Feb 24 | Joseph Edward Tucker | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 174,196 |
22 Feb 24 | Peter J. Facchini | Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0.00 | 90,856 |
22 Feb 24 | Kevin Michael Coveney | Common Stock | Grant | Acquire A | No | No | 0 | 60,000 | 0.00 | 86,500 |
15 Sep 23 | Pasqualone Frank | Common Stock | Buy | Acquire P | No | No | 2.14 | 1,000 | 2.14 k | 1,000 |
News
Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth
27 Mar 24
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
20 Mar 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
19 Mar 24
Enveric Biosciences Canada Granted U.S. Patent #11931338: Nitrilated psilocybin derivatives and methods of using
19 Mar 24
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
19 Mar 24
Press releases
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
19 Mar 24
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
12 Mar 24
Thinking about buying stock in SoundHound AI, Coinbase Global, Societal CDMO, Enveric Biosciences, or Royalty Management Holding?
29 Feb 24
Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB
28 Feb 24
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property
23 Feb 24